AKL

The Vanuatu Trade Commission To Ghana Partners ECO-6 For Development In Vanuatu and West Africa

Retrieved on: 
Tuesday, January 2, 2024

MIAMI, Jan. 2, 2024 /PRNewswire-PRWeb/ -- The Vanuatu Trade Commission of Ghana has signed an agreement with the African Diaspora Central Bank (ADCB)/ Eco-6 Lumi as its strategic trading partners for the Republic of Vanuatu and the West African sub-regional countries.

Key Points: 
  • MIAMI, Jan. 2, 2024 /PRNewswire-PRWeb/ -- The Vanuatu Trade Commission of Ghana has signed an agreement with the African Diaspora Central Bank (ADCB)/ Eco-6 Lumi as its strategic trading partners for the Republic of Vanuatu and the West African sub-regional countries.
  • The Vanuatu Trade Commission Ghana represents a sovereign trading partner of the Economic Community of West African States (ECOWAS) while ECO-6 invests in members and trade partners of African Regional Economic Communities (RECs).
  • We embrace this agreement as a sign of hope for our jurisdictional relevance of the Vanuatu Trade Commission.
  • Million Africans and our Diaspora families benefit through financial stimulus packages from the Vanuatu Trade Commission and ADCB.

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on: 
Monday, March 20, 2023

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points: 
  • STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
    The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
    Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
    "Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
  • "8
    As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
    Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
    David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
  • With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
  • APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
    There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24

New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

Retrieved on: 
Monday, March 20, 2023

STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3

Key Points: 
  • STEVENAGE, England, March 20, 2023 /PRNewswire/ -- New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggest that AKL Therapeutics' investigational oral osteoarthritis (OA) drug APPA** may have a dual effect on senescence1 – a process in which cells stop dividing as a natural consequence of ageing.2 Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).3
    The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain.1 It found that APPA appears to not only reduce the number of harmful senescent cells which build up in the cartilage causing inflammation (a 'senolytic' effect), but could also potentially reverse the senescence process so cells can function normally again (a 'senomorphic' effect).1,4
    Alan Reynolds, Chief Scientific Officer at AKL Therapeutics, says: "These latest findings raise the tantalising possibility that APPA could modify the progression of debilitating OA for patients by eliminating or delaying the adverse effects of cellular senescence and the process of ageing.3
    "Frailty and mobility issues have a significant impact as we age, often leading to people living many years in pain and ill health.5,6 If we can reduce senescence, which contributes to joint damage in OA7 and is involved in many other age-related diseases, we can hopefully help improve peoples' healthspan, so they age in better physical and mental health.
  • "8
    As we age, dysfunctional senescent cells – often dubbed "zombie" cells – build up in the body while secreting harmful chemicals which cause inflammation and damage surrounding tissue – a process known as senescence.2 They have become one of the most promising targets for healthy ageing research as senescence is now known to play a major role in the development of many age-related diseases, including OA, Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's Disease, Parkinson's Disease, osteoporosis, and diabetes.9
    Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence is a new frontier in medicine.10 Senotherapeutics have the potential to increase healthspan by delaying the worse effects of ageing, which would reduce the burden of age-related diseases and could save healthcare systems billions every year.11
    David Miles, Chief Executive Officer at AKL Therapeutics, says: "With a unique mechanism of action,12-15 APPA is the only oral drug that targets the multiple signalling pathways in bone, cartilage and inflammation involved in OA, delivering pain relief to multiple joints.
  • With this latest data now showing that APPA has a potential senomorphic effect, we've recently filed a patent application and will look to carry out further studies on other senescence-related diseases to investigate its potential as a senotherapeutic."
  • APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.16,17 Previous human clinical trials have shown that APPA has a good safety profile, is well-tolerated and reduces pain in OA.18,19 Importantly, it has been shown to reduce levels of cartilage-damaging enzymes and levels of bone destruction.13-15 The Phase 2a trial found that those with more severe disease benefited most from APPA with a statistically significant improvement in pain vs placebo.18
    There are currently no effective and well tolerated oral therapies that provide long-term pain relief or reduce the progression of OA, a common, debilitating, degenerative disease of the joints involving the cartilage, bone, and its surrounding tissues.22 OA is the most common joint disease worldwide, affecting an estimated 10% of men and 18% of women over 60 years of age.23 Globally, the prevalent cases of OA increased by 113.25%, from 247.51 million in 1990 to 527.81 million in 2019, with OA of the knee contributing most to the overall burden.24

Air New Zealand touches down in the Big Apple

Retrieved on: 
Sunday, September 18, 2022

Minister of Tourism for New Zealand Hon Stuart Nash, Chair Dame Therese Walsh and Air New Zealand Chief Executive Officer Greg Foran were onboard the inaugural flight, along with key tourism and travel partners.

Key Points: 
  • Minister of Tourism for New Zealand Hon Stuart Nash, Chair Dame Therese Walsh and Air New Zealand Chief Executive Officer Greg Foran were onboard the inaugural flight, along with key tourism and travel partners.
  • "As one of the world's greatest cities, Air New Zealand is proud to add the Big Apple to its list of 29 international destinations.
  • The airline's new international menu was debuted onboard NZ2, showcasing the best of New Zealand produce to the world.
  • Air New Zealand now serves seven destinations in North America Chicago (from 31 October), Honolulu, Houston, Los Angeles, San Francisco, Vancouver and (after much anticipation), New York City.

Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo® Branded Ingredient from FDA

Retrieved on: 
Thursday, August 25, 2022

FDA has responded with a no objection letter, also called an Acknowledgement (AKL) Without Comment Letter.

Key Points: 
  • FDA has responded with a no objection letter, also called an Acknowledgement (AKL) Without Comment Letter.
  • The AKL response letter from FDA for ProGo is the highest safety rating and attestation the Client could have received for its dietary ingredient.
  • This achievement follows on the heels of successful receipt of the same accolades for both CalGo and OmeGo late last year.
  • Consumers and retailers are starting to understand what it means to have an AKL no-objection letter from the FDA.

NFT Collector buys all 63 National Parks NFTs

Retrieved on: 
Monday, April 11, 2022

National Parks NFT sold out their 4.8K collection in 7 minutes back in January as club membership for national park superfans.

Key Points: 
  • National Parks NFT sold out their 4.8K collection in 7 minutes back in January as club membership for national park superfans.
  • One collector decided to go all-in, buying an NFT for each of the 63 national parks - investing over $30,000 for this achievement.
  • The National Parks NFT team quickly organized a Twitter Spaces event to interview the collector who goes by the nickname "AKL". "
  • The National Parks NFT artwork show the unique features of the National Parks.